Thu, 02nd Dec 2021 07:09
Dec 2 (Reuters) - GlaxoSmithKline on Thursday said
that a pre-clinical analysis of the antibody-based COVID-19
therapy it is developing with U.S. partner Vir has
indicated that the drug also works against the new Omicron
variant.
Further tests will be carried out on the sotrovimab therapy
to firm up the results, GSK said in a statement.
(Reporting by Ludwig Burger
Editing by David Goodman
)
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but th...
(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its disc...
(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.
(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.
(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidi...
Glaxosmithkline (GSK)